CN103212083A - Method for preparing stable albumin nano-particles - Google Patents
Method for preparing stable albumin nano-particles Download PDFInfo
- Publication number
- CN103212083A CN103212083A CN2013101245919A CN201310124591A CN103212083A CN 103212083 A CN103212083 A CN 103212083A CN 2013101245919 A CN2013101245919 A CN 2013101245919A CN 201310124591 A CN201310124591 A CN 201310124591A CN 103212083 A CN103212083 A CN 103212083A
- Authority
- CN
- China
- Prior art keywords
- albumin
- nanometer
- particulate
- aqueous solution
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention discloses a method for preparing stable albumin nano-particles, belonging to the technical field of biological medicine material preparation. The method comprises the following steps of: carrying out pretreatment on albumin by utilizing non-biotoxic glutathione or cysteine to open intramolecular dithio bonds, precipitating the albumin by using anti-solvents such as alcohol and the like, and carrying out sulfydryl-dithio bond exchange reaction so as to obtain albumin nano-particles with intermolecular dithio bonds. The prepared nano-particles can be used for delivering in-vivo pharmacologically active substances and/or diagnosis aids. The obtained albumin nano-particles have the advantages that the albumin nano-particles not only have good stability under dilution condition, but also have oxidation reduction response in a reduction type environment; and due to such characteristics, the particles can stably exist in in-vivo blood circulation systems of organisms and are degraded under the action of reduced glutathione so as to release the wrapped medicine.
Description
Technical field
The present invention relates to the particulate preparation method of a kind of albumin nanometer, belong to the biological medicine technical field of material.
Background technology:
Albumin is a kind of biological endogenous property albumen, and many characteristics such as biodegradable, nontoxic, no antigen that has are considered to an ideal pharmaceutical carrier, and the albumin medicine-carried system is research direction that has vitality in the study of pharmacy now.The albumin medicine-carried system mainly is divided into two big classes, and a class is the albumin medicine-carried system of chemical coupling, and another kind of is the albumin medicine-carried system of physical bond.The albumin of chemical coupling can improve the pharmacokinetic properties of medicine, but has formed new chemical molecular after the combination.The albumin drug delivery system of physical bond form is an even more ideal medicine carrying pattern, drug molecule is wrapped in the albumin nanometer granule, can obviously improves water-insoluble medicine stability and dissolubility of (being in the body inner blood blood circulation) in aqueous solution.Simultaneously, utilize the permeability of tumor tissues to strengthen and retention effect (EPR effect), can be so that albumin nanometer rice medicine-carried system reaches the purpose of target administration.
Because the albumin molecule has fabulous water solublity, how to make albumin nanometer granule that good stable is arranged in water, not dissolving under diluting condition is difficult point on the present technology of preparing.Cross-linking agent such as glutaraldehyde often are used to the stable nano-particle that obtains, but the amino sites on the nonselective albumin-binding of glutaraldehyde meeting surface can discharge the aldehydes residue in vivo, and organism is had remarkable toxic and side effects.The albumin nano granular synthetic technology (CN102048695A) that a kind of self assembly of report is arranged, utilize mercaptoethanol etc. to open the disulfide bond of albumin molecule as Reducing agent, make it utilize hydrophobic interaction to be combined into nano-particle, but this granule is i.e. all dissolvings in 10% ethanol water, illustrate that this granule only depends on hydrophobic interaction stable, and are not stable (the Gong M.G.et al. of disulfide-bonded, Biomacromolecules, 2012,13,23-28).American Bioscience company has developed a kind of nab technology (Nanoparticle albumin-bound technology) that forms based on disulfide bond, as substrate and stabilizing agent, under the situation that does not add any emulsifying agent and cross-linking agent, make albumin nano granular (US6753006B1) with albumin.But in recent years to Abraxane product dilution experiment (Chauhan V.P.et al., Nature Nanotech., 2012,7,383-388. show, after Abraxane is diluted in buffer solution or the bovine serum albumin solution, can be decomposed into the granule of the size about 10nm at once, this shows that this product is not to be got by disulfide bond crosslinking yet.
Summary of the invention:
The purpose of this invention is to provide a kind of stable particulate method of albumin nanometer for preparing, this albumin nano granular is crosslinked and stable by intermolecular disulfide bond, is difficult to carry out the problem of sending in the body in order to solve some pharmacological active substance.
In order to realize purpose of the present invention, technical scheme of the present invention is:
A kind ofly prepare the stable particulate method of albumin nanometer, following steps are carried out:
1) preparation volume mass concentration is the albumin aqueous solution of 10～200mg/mL;
2) in the albumin aqueous solution, add glutathion or cysteine, make its molar concentration in the albumin aqueous solution reach 10～500mM, react 5～240min down for 10～60 ℃ in temperature;
3) in step 2) add the ethanol or the tert-butyl alcohol in the reacted solution, under 10～60 ℃ of temperature, reaction 5～120min obtains the crosslinked particulate suspension of albumin nanometer of intermolecular disulfide bond; The ethanol of described albumin aqueous solution and adding or the volume ratio of the tert-butyl alcohol are 1:1～5;
4) the particulate suspension of albumin nanometer is dialysed down for 0～20 ℃ in temperature, obtain albumin nanometer particle solution, carry out processed through lyophilization, spray drying or distilling under reduced pressure again, obtain albumin nanometer granule.
A kind of particulate preparation method of albumin nanometer that is used to send pharmacology active medicine in the body, carry out as follows:
1) preparation volume mass concentration is the albumin aqueous solution of 10～200mg/mL;
2) in the albumin aqueous solution, add glutathion or cysteine, make its molar concentration in the albumin aqueous solution reach 10～500mM, react 5～240min down for 10～60 ℃ in temperature;
3) in step 2) add the alcoholic solution of pharmacologically active medicine or the t-butanol solution of pharmacologically active medicine in the reacted solution, at 10～60 ℃ of temperature reaction 5～120min down, obtain wrapping up the particulate suspension of albumin nanometer of pharmacological active substance; The volume ratio of the alcoholic solution of the pharmacologically active medicine of described albumin aqueous solution and adding or the t-butanol solution of pharmacologically active medicine is 1:1～5;
4) the particulate suspension of albumin nanometer is dialysed down for 0～20 ℃ in temperature, obtain wrapping up the particulate solution of albumin nanometer of pharmacological active substance, carry out processed through lyophilization, spray drying or distilling under reduced pressure again, obtain wrapping up the albumin nanometer granule of pharmacological active substance.
The albumin nano granular mean diameter that obtains in the technical solution of the present invention is 10～500nm.
Albumin molecule described in the technical solution of the present invention comprise the human serum albumin (human serum albumin, HSA), bovine serum albumin (bovine serum albumin, BSA), recombination human serum albumin (recombinant HSA, rHSA), or their combination.
Can wrap in the albumin nanometer granule of the parcel pharmacological active substance described in the technical solution of the present invention and carry the pharmacological active substance that accounts for nanoparticle total amount 1%～90%.
Pharmacological active substance described in the technical solution of the present invention is a cancer therapy drug.
Cancer therapy drug described in the technical solution of the present invention comprises paclitaxel, Docetaxel, amycin, curcumin, platinum and analog thereof, methotrexate or their combination.
The particulate advantage of albumin nanometer of the prepared albumin nanometer of the present invention granule and parcel pharmacological active substance is: the albumin in the nano-particle has intermolecular disulfide bond crosslinked, equal stable existence in the aqueous solution between pH scope 3-4 and 6-10, in volume fraction is stable existence in 1～50% the ethanol water, and (37 ℃ of physiological conditions, pH=7.4) stable existence in the dilution experiment under, this granule can progressively dissolve in the reproducibility environment simultaneously.Above characteristic make this granule can stable existence in organism inner blood blood circulation, and degraded and discharge the medicine that is wrapped up under the effect of reduced glutathion in cell.
Description of drawings:
Fig. 1 is the stability study of albumin nano granular in the different solvents environment among the present invention.
Fig. 2 is the SDS-PAGE electrophoretogram of albumin nano granular among the present invention after progressively dissolving under the reduced form condition.Wherein, 1 is the band of albumin nano granular, and 2 is the band of albumin oligomer, and 3 is albumin dimer and trimerical band, and 4 is the monomolecular band of albumin.
Fig. 3 is the surface sweeping electron microscope image and the transmission electron microscope image of albumin-curcumin nanoparticles among the present invention.Wherein, A and B are the surface sweeping electron microscope image, and C and D are transmission electron microscope image.
The specific embodiment:
A kind of stable particulate method of albumin nanometer for preparing provided by the invention, this method is carried out as follows:
1) preparation volume mass concentration is the albumin aqueous solution of 10～200mg/mL; Described albumin generally adopts human serum albumin, bovine serum albumin, recombination human serum albumin or their combination.
2) in the albumin aqueous solution, add glutathion or cysteine, make its molar concentration in the albumin aqueous solution reach 10～500mM, react 5～240min down for 10～60 ℃ in temperature;
3) in step 2) add the ethanol or the tert-butyl alcohol in the reacted solution, at 10～60 ℃ of temperature reaction 5～120min down, obtain the crosslinked particulate suspension of albumin nanometer of intermolecular disulfide bond; The ethanol of described albumin aqueous solution and adding or the volume ratio of the tert-butyl alcohol are 1:1～5;
4) the particulate suspension of albumin nanometer is dialysed down for 0～20 ℃ in temperature, obtain albumin nanometer particle solution, carry out processed through lyophilization, spray drying or distilling under reduced pressure again, obtain albumin nanometer granule.The albumin nano granular mean diameter that obtains is 10～500nm.
A kind of particulate preparation method of albumin nanometer that is used to send pharmacology active medicine in the body provided by the invention, this method is carried out as follows:
1) preparation volume mass concentration is the albumin aqueous solution of 10～200mg/mL;
2) in the albumin aqueous solution, add glutathion or cysteine, make its molar concentration in the albumin aqueous solution reach 10～500mM, react 5～240min down for 10～60 ℃ in temperature;
3) in step 2) add the alcoholic solution of pharmacologically active medicine or the t-butanol solution of active medicine in the reacted solution, at 10～60 ℃ of temperature reaction 5～120min down, obtain wrapping up the particulate suspension of albumin nanometer of pharmacological active substance; The volume ratio of the alcoholic solution of the pharmacologically active medicine of described albumin aqueous solution and adding or the t-butanol solution of pharmacologically active medicine is 1:1～5; Pharmacological active substance is a cancer therapy drug, for example the analog of paclitaxel, Docetaxel, amycin, curcumin, platinum and platinum, methotrexate or their combination.
4) the particulate suspension of albumin nanometer is dialysed down for 0～20 ℃ in temperature, obtain wrapping up the particulate solution of albumin nanometer of pharmacological active substance, carry out processed through lyophilization, spray drying or distilling under reduced pressure again, obtain wrapping up the albumin nanometer granule of pharmacological active substance.The pharmacological active substance that bag carries in the albumin nano granular accounts for 1%～90% of nanoparticle total amount.
For a better understanding of the present invention, below in conjunction with five examples the present invention is described in further details.But protection domain of the present invention is not limited to the expressed scope of embodiment.
Experimental technique described in the following embodiment if no special instructions, is conventional method; Described reagent and material if no special instructions, all can obtain from commercial channels.
Embodiment 1, the stable human serum albumin's nano-particle of preparation disulfide bond.
With human serum albumin and reduced glutathion is raw material, the stable human serum albumin's nano-particle of preparation disulfide bond.
Concrete preparation method is as follows:
Human serum albumin 20mg is dissolved in the aqueous solution of 1mL, and adding 20mM reduced glutathion, reaction is 1 hour under the room temperature, add 4mL dehydrated alcohol reaction 30 minutes then, subsequently with prepared suspension as in the bag filter, in the deionized water under 4 ℃ environment the dialysis 24 hours, promptly obtain the stable human serum albumin's nano-particle of disulfide bond, and the mean diameter of albumin nano granular is 100～300nm(ZetaPALS, Zeta Potential Analyzer).
The stability of prepared nano-particle in the different solvents environment can be as seen from Figure 1.The progressively course of dissolution of prepared nano-particle under reducing environment can obtain confirming from the SDS-PAGE gel electrophoresis figure of Fig. 2.
Embodiment 2, the stable human serum albumin's nano-particle of preparation disulfide bond.
With human serum albumin and reduced glutathion is raw material, the stable human serum albumin's nano-particle of preparation disulfide bond.
Concrete preparation method is as follows:
Human serum albumin 200mg is dissolved in the aqueous solution of 1mL, and adding 500mM reduced glutathion, 50 ℃ were reacted 10 minutes, add 1mL dehydrated alcohol reaction 5 minutes then, then with prepared suspension as in the bag filter, dialysis is 24 hours in the deionized water under 10 ℃ environment, promptly obtain the stable human serum albumin's nano-particle of disulfide bond, and the mean diameter of albumin nano granular is 100～400nm.
Embodiment 3, the stable curcumin-human serum albumin's nano-particle medicine-carried system of preparation disulfide bond.
With the human serum albumin, reduced glutathion and curcumin are raw material, and the stable human serum albumin of preparation disulfide bond coats the nano-particle medicine-carried system of curcumin.
Concrete preparation method is as follows:
Human serum albumin 40mg is dissolved in the aqueous solution of 1mL, and adding 50mM reduced glutathion, reaction is 1 hour under the room temperature, the 3mg/mL curcumin alcoholic solution that adds 4mL then reacted 30 minutes, subsequently with prepared suspension as in the bag filter, dialysis is 24 hours in the deionized water under 4 ℃ environment, promptly obtains the stable curcumin-human serum albumin of disulfide bond and wraps nano-particle.And the mean diameter of nanoparticle is 50～400nm(ZetaPALS, Zeta Potential Analyzer), firmly measure the drug loading of curcumin with anti-phase C18, mobile phase is methanol: water: acetic acid (80:19:1), the detection wavelength is 428nm.HPLC the analysis showed that the curcumin drug loading of this experiment reaches 21%.Prepared nano-particle pattern obtains confirming from the sem image of Fig. 3.
Embodiment 4, the stable curcumin-human serum albumin's nano-particle medicine-carried system of preparation disulfide bond.
With the human serum albumin, reduced glutathion and curcumin are raw material, and the stable human serum albumin of preparation disulfide bond coats the nano-particle medicine-carried system of curcumin.
Concrete preparation method is as follows:
Human serum albumin 10mg is dissolved in the aqueous solution of 1mL, and adding 50mM reduced glutathion, reaction is 1 hour under the room temperature, the 3mg/mL curcumin alcoholic solution that adds 4mL then reacted 30 minutes, subsequently with prepared suspension as in the bag filter, dialysis is 24 hours in the deionized water under 4 ℃ environment, promptly obtains the stable curcumin-human serum albumin of disulfide bond and wraps nano-particle.The mean diameter of prepared nanoparticle is 50～400nm, and HPLC the analysis showed that the curcumin drug loading of this experiment reaches 40%.
Embodiment 5, the stable paclitaxel-human serum albumin's nano-particle of preparation disulfide bond.
With the human serum albumin, reduced glutathion and paclitaxel are raw material, the stable paclitaxel-human serum albumin's nano-particle medicine-carried system of preparation disulfide bond.
Concrete preparation method is as follows:
Human serum albumin 40mg is dissolved in the aqueous solution of 1mL, and adding 50mM reduced glutathion, 25 ℃ were reacted 4 hours down, the t-butanol solution that adds the 2.5mg/mL paclitaxel of 3.5mL was then reacted 30 minutes, subsequently with prepared suspension as in the bag filter, dialysis is 24 hours in the deionized water under 4 ℃ environment, promptly obtains the stable paclitaxel-human serum albumin of disulfide bond and wraps nano-particle.The mean diameter of prepared nanoparticle is 50～400nm, and HPLC the analysis showed that the paclitaxel carried medicine amount of this experiment reaches 10%.
Claims (7)
1. one kind prepares the stable particulate method of albumin nanometer, it is characterized in that this method carries out as follows:
1) preparation volume mass concentration is the albumin aqueous solution of 10～200mg/mL;
2) in the albumin aqueous solution, add glutathion or cysteine, make its molar concentration in the albumin aqueous solution reach 10～500mM, react 5～240min down for 10～60 ℃ in temperature;
3) in step 2) add the ethanol or the tert-butyl alcohol in the reacted solution, at 10～60 ℃ of temperature reaction 5～120min down, obtain the crosslinked particulate suspension of albumin nanometer of intermolecular disulfide bond; The ethanol of described albumin aqueous solution and adding or the volume ratio of the tert-butyl alcohol are 1:1～5;
4) the particulate suspension of albumin nanometer is dialysed down for 0～20 ℃ in temperature, obtain albumin nanometer particle solution, carry out processed through lyophilization, spray drying or distilling under reduced pressure again, obtain albumin nanometer granule.
2. a kind of stable particulate method of albumin nanometer for preparing according to claim 1, it is characterized in that: described albumin nano granular mean diameter is 10～500nm.
3. a kind of stable particulate method of albumin nanometer for preparing according to claim 1, it is characterized in that: described albumin comprises human serum albumin, bovine serum albumin, recombination human serum albumin or their combination.
4. particulate preparation method of albumin nanometer that is used to send pharmacology active medicine in the body is characterized in that this method carries out as follows:
1) preparation volume mass concentration is the albumin aqueous solution of 10～200mg/mL;
2) in the albumin aqueous solution, add glutathion or cysteine, make its molar concentration in the albumin aqueous solution reach 10～500mM, react 5～240min down for 10～60 ℃ in temperature;
3) in step 2) add the alcoholic solution of pharmacologically active medicine or the t-butanol solution of active medicine in the reacted solution, at 10～60 ℃ of temperature reaction 5～120min down, obtain wrapping up the particulate suspension of albumin nanometer of pharmacological active substance; The volume ratio of the alcoholic solution of the pharmacologically active medicine of described albumin aqueous solution and adding or the t-butanol solution of pharmacologically active medicine is 1:1～5;
4) the particulate suspension of albumin nanometer is dialysed down for 0～20 ℃ in temperature, obtain wrapping up the particulate solution of albumin nanometer of pharmacological active substance, carry out processed through lyophilization, spray drying or distilling under reduced pressure again, obtain wrapping up the albumin nanometer granule of pharmacological active substance.
5. a kind of particulate preparation method of albumin nanometer that is used to send the activity in vivo medicine according to claim 4 is characterized in that: the pharmacological active substance that bag carries in the described albumin nano granular accounts for 1%～90% of nanoparticle total amount.
6. a kind of particulate preparation method of albumin nanometer that is used to send pharmacology active medicine in the body according to claim 4, it is characterized in that: described pharmacological active substance is a cancer therapy drug.
7. a kind of particulate preparation method of albumin nanometer that is used to send the activity in vivo medicine according to claim 6, it is characterized in that: described cancer therapy drug comprises analog, methotrexate or their combination of paclitaxel, Docetaxel, amycin, curcumin, platinum and platinum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310124591.9A CN103212083B (en) | 2012-12-19 | 2013-04-11 | Method for preparing stable albumin nano-particles |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210555653 CN102988996A (en) | 2012-12-19 | 2012-12-19 | Method for preparing stable albumin nanoparticle |
| CN201210555653.7 | 2012-12-19 | ||
| CN201310124591.9A CN103212083B (en) | 2012-12-19 | 2013-04-11 | Method for preparing stable albumin nano-particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103212083A true CN103212083A (en) | 2013-07-24 |
| CN103212083B CN103212083B (en) | 2014-09-17 |
Family
ID=47918427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210555653 Pending CN102988996A (en) | 2012-12-19 | 2012-12-19 | Method for preparing stable albumin nanoparticle |
| CN201310124591.9A Active CN103212083B (en) | 2012-12-19 | 2013-04-11 | Method for preparing stable albumin nano-particles |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210555653 Pending CN102988996A (en) | 2012-12-19 | 2012-12-19 | Method for preparing stable albumin nanoparticle |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102988996A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104043135A (en) * | 2014-06-13 | 2014-09-17 | 苏州大学 | Albumin indocyanine green paclitaxel compound as well as preparation method and application thereof |
| CN104162172A (en) * | 2013-09-27 | 2014-11-26 | 深圳先进技术研究院 | Paclitaxel-containing polymer albumin nanosphere and preparation method and application thereof |
| CN107157933A (en) * | 2017-05-04 | 2017-09-15 | 同济大学 | A kind of albumen self assembly novel nano vaccine and preparation method thereof |
| CN108379228A (en) * | 2018-02-28 | 2018-08-10 | 湖南大学 | A kind of albumin nanoparticle and its preparation method and application of package pharmacological active substance |
| CN109771656A (en) * | 2019-03-12 | 2019-05-21 | 四川载荧生物科技有限公司 | The preparation method of Novel albumin Nano medication under a kind of 37 DEG C of temperate conditions |
| CN115887677A (en) * | 2022-11-03 | 2023-04-04 | 嘉兴学院 | Preparation method and application of protein bionic capsule |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520734B (en) * | 2013-09-29 | 2016-01-20 | 中国科学院过程工程研究所 | A kind of based on albuminous nanoparticle, Preparation Method And The Use |
| WO2015018380A2 (en) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
| CN104306339A (en) * | 2014-10-22 | 2015-01-28 | 南京大学 | Thymidylate synthase preparation loaded albumin nano-microsphere and preparation method thereof |
| CN104758251B (en) * | 2015-04-30 | 2018-06-12 | 重庆医科大学 | Preparation based on albumin for the load curcumin liver-targeted nanometer grain of carrier material |
| CN105832676B (en) * | 2016-03-28 | 2018-11-20 | 湖南大学 | A kind of preparation method of arsenic trioxide albumin nano drug |
| CN108295046A (en) * | 2016-12-30 | 2018-07-20 | 中国科学院深圳先进技术研究院 | The preparation method and albumin nanoparticle obtained of a kind of albumin nanoparticle and application |
| CN106719636B (en) * | 2017-01-13 | 2022-03-18 | 北京林业大学 | Preparation method of novel pesticide bovine serum albumin-thiacloprid nanoparticles |
| CN107952072B (en) * | 2017-11-28 | 2021-07-20 | 深圳先进技术研究院 | Preparation method of drug-loaded and oxygen-loaded hybrid protein nanoparticles, drug-loaded and oxygen-loaded hybrid protein nanoparticles and application |
| CN108478805B (en) * | 2018-02-28 | 2021-02-26 | 湖南大学 | Novel albumin-siRNA composite nano-particles and preparation method and application thereof |
| CN109453389B (en) * | 2018-12-24 | 2022-04-15 | 苏州大学 | Folic acid receptor mediated tumor internal environment sensitive adriamycin albumin nano particle and preparation method thereof |
| CN110496229B (en) * | 2019-09-16 | 2022-09-23 | 上海市肺科医院 | Nanoparticle-coated antibacterial peptide with slow release property and preparation method thereof |
| CN111407741A (en) * | 2020-03-23 | 2020-07-14 | 太原理工大学 | Anti-cancer drug carrier with redox and pH dual responses and preparation method and application thereof |
| CN111529506B (en) * | 2020-05-18 | 2021-09-03 | 同济大学 | Amphotericin B albumin nano preparation and preparation method and application thereof |
| AU2022230634A1 (en) * | 2021-03-05 | 2023-09-21 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Stable docetaxel albumin nanoparticle composition |
| CN113456612A (en) * | 2021-06-21 | 2021-10-01 | 上海市胸科医院 | Albumin drug delivery system for treating sepsis myocardial injury |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| CN102048695A (en) * | 2009-08-11 | 2011-05-11 | 南京大学 | Preparation method of protein nanoparticle for in vivo delivery of pharmacologically active agent |
-
2012
- 2012-12-19 CN CN 201210555653 patent/CN102988996A/en active Pending
-
2013
- 2013-04-11 CN CN201310124591.9A patent/CN103212083B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| CN102048695A (en) * | 2009-08-11 | 2011-05-11 | 南京大学 | Preparation method of protein nanoparticle for in vivo delivery of pharmacologically active agent |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104162172B (en) * | 2013-09-27 | 2017-06-23 | 深圳先进技术研究院 | A kind of polymer albumin nanospheres comprising taxol and its preparation method and application |
| CN104162164B (en) * | 2013-09-27 | 2017-06-23 | 深圳先进技术研究院 | A kind of polymer albumin nanospheres comprising indocyanine-green and its preparation method and application |
| CN104162164A (en) * | 2013-09-27 | 2014-11-26 | 深圳先进技术研究院 | Indocyanine green-containing polymer albumin nanosphere and preparation method and application thereof |
| CN104189916A (en) * | 2013-09-27 | 2014-12-10 | 深圳先进技术研究院 | Multimer alhumin nanospheres, and preparation method and application thereof |
| CN104189916B (en) * | 2013-09-27 | 2017-05-10 | 深圳先进技术研究院 | Multimer alhumin nanospheres, and preparation method and application thereof |
| CN104162171B (en) * | 2013-09-27 | 2017-06-23 | 深圳先进技术研究院 | A kind of polymer albumin nanospheres comprising chlorin e 6 and its preparation method and application |
| CN104162172A (en) * | 2013-09-27 | 2014-11-26 | 深圳先进技术研究院 | Paclitaxel-containing polymer albumin nanosphere and preparation method and application thereof |
| CN104043135A (en) * | 2014-06-13 | 2014-09-17 | 苏州大学 | Albumin indocyanine green paclitaxel compound as well as preparation method and application thereof |
| CN107157933A (en) * | 2017-05-04 | 2017-09-15 | 同济大学 | A kind of albumen self assembly novel nano vaccine and preparation method thereof |
| CN108379228A (en) * | 2018-02-28 | 2018-08-10 | 湖南大学 | A kind of albumin nanoparticle and its preparation method and application of package pharmacological active substance |
| CN108379228B (en) * | 2018-02-28 | 2021-02-23 | 湖南大学 | Albumin nano-particles wrapping pharmacological active substances and preparation method and application thereof |
| CN109771656A (en) * | 2019-03-12 | 2019-05-21 | 四川载荧生物科技有限公司 | The preparation method of Novel albumin Nano medication under a kind of 37 DEG C of temperate conditions |
| CN115887677A (en) * | 2022-11-03 | 2023-04-04 | 嘉兴学院 | Preparation method and application of protein bionic capsule |
| CN115887677B (en) * | 2022-11-03 | 2024-04-12 | 嘉兴学院 | Preparation method and application of protein bionic capsules |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103212083B (en) | 2014-09-17 |
| CN102988996A (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103212083B (en) | Method for preparing stable albumin nano-particles | |
| Yadav et al. | Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation | |
| Grumezescu | Organic materials as smart nanocarriers for drug delivery | |
| Sarkar et al. | Protein nanocomposites: Special inferences to lysozyme based nanomaterials | |
| Huang et al. | New advances in gated materials of mesoporous silica for drug controlled release | |
| CN102250365B (en) | PH-sensitive reduction responsive nanogel and preparation method thereof | |
| Athar et al. | Therapeutic nanoparticles: State-of-the-art of nanomedicine | |
| Yang et al. | Targeted polysaccharide nanoparticle for adamplatin prodrug delivery | |
| CN108379228B (en) | Albumin nano-particles wrapping pharmacological active substances and preparation method and application thereof | |
| Sironmani et al. | Silver nanoparticles–universal multifunctional nanoparticles for bio sensing, imaging for diagnostics and targeted drug delivery for therapeutic applications | |
| Zhang et al. | Nanoscale bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates for selective cancer therapy | |
| Khalaf et al. | Recent progressions in biomedical and pharmaceutical applications of chitosan nanoparticles: A comprehensive review | |
| Pei et al. | Facile synthesis of fluorescent hyper-cross-linked β-cyclodextrin-carbon quantum dot hybrid nanosponges for tumor theranostic application with enhanced antitumor efficacy | |
| Yang et al. | Nanostructured antimicrobial peptides: crucial steps of overcoming the bottleneck for clinics | |
| Tran et al. | Fucoidan-based nanostructures: A focus on its combination with chitosan and the surface functionalization of metallic nanoparticles for drug delivery | |
| Uthaman et al. | Carbohydrate-based nanogels as drug and gene delivery systems | |
| Han et al. | Functionalization and optimization-strategy of graphene oxide-based nanomaterials for gene and drug delivery | |
| Gaudana et al. | Encapsulation of protein-polysaccharide HIP complex in polymeric nanoparticles | |
| Cao et al. | Horseradish peroxidase-encapsulated chitosan nanoparticles for enzyme-prodrug cancer therapy | |
| Ng et al. | Conjugation of insulin onto the sidewalls of single-walled carbon nanotubes through functionalization and diimide-activated amidation | |
| Kumari | A Review on Nanoparticles: Their Preparation method and applications | |
| Singh et al. | Nanogel based artificial chaperone technology: an overview | |
| WO2009079688A1 (en) | Porous silica shell-mediated assembly of macromolecular capsules | |
| Latorre et al. | Glutathione-triggered drug release from nanostructures | |
| Huang et al. | Self-assembled nanoparticles based on a cationic conjugated polymer/hyaluronan–cisplatin complex as a multifunctional platform for simultaneous tumor-targeting cell imaging and drug delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |